Analyst Reco. Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
5.87 ^USD	-0.51%		+8.30%	-3.29%

24/04	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
24/04	Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating	04/03	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $8 From $6, Maintains Overweight Rating	29/01	MT
Truist Adjusts Amneal Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	07/23/07	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $5 From $4, Maintains Overweight Rating	07/23/07	MT
Piper Sandler Adjusts Amneal Pharmaceuticals' Price Target to $3 From $5, Keeps Overweight Rating	08/23/08	MT
Truist Securities Trims Amneal Pharmaceuticals' Price Target to $4 From $5, Maintains Buy Rating	28/23/28	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $4 From $7, Keeps Overweight Rating	10/23/10	MT
Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $3 From $3.50, Maintains Buy Rating	03/23/03	MT
BMO Capital Adjusts Price Target on Amneal Pharmaceuticals to $4 From $5, Maintains Market Perform Rating	03/23/03	MT
Goldman Sachs Trims Amneal Pharmaceuticals Price Target to $4 From $4.50, Maintains Buy Rating	08/22/08	MT
Truist Securities Trims Amneal Pharmaceuticals' Price Target to $6 From $7, Maintains Buy Rating	01/22/01	MT
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $4.50 From $6, Maintains Buy Rating	12/22/12	MT
Amneal Pharmaceuticals : Moody's Upgrades Amneal Pharmaceuticals Ratings One Notch to B2; Outlook Stable	14/21/14	MT
AMNEAL PHARMACEUTICALS : Guggenheim Adjusts Amneal Pharmaceuticals' Price Target to $8 From $6.50, Maintains Buy Rating	14/21/14	MT
AMNEAL PHARMACEUTICALS : Goldman Sachs Upgrades Amneal Pharmaceuticals to Buy From Sell, Adjusts Price Target to $6.50 From $4	08/21/08	MT
AMNEAL PHARMACEUTICALS : Barclays Adjusts Amneal Pharmaceuticals PT to $8 From $6, Maintains Overweight Rating	01/21/01	MT
AMNEAL PHARMACEUTICALS : RBC Capital Adjusts Price Target on Amneal Pharmaceuticals to $5 From $4, Keeps Sector Perform Rating	01/21/01	MT
AMNEAL PHARMACEUTICALS : Morgan Stanley Adjusts PT on Amneal Pharmaceuticals to $5 From $3, Citing 'Ability to Deliver on Cost Efficiencies,' Margin Expansion; Equal-Weight Rating Kept	21/20/21	MT
AMNEAL PHARMACEUTICALS : Barclays Upgrades Amneal Pharmaceuticals to Overweight From Equal-Weight; Price Target is $6	14/20/14	MT
AMNEAL PHARMACEUTICALS : Guggenheim Upgrades Amneal Pharmaceuticals to Buy From Neutral; Price Target is $5.50	14/20/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Analyst Reco.

Filters